|
Angiopoietin-2 + VEGF-A to treat DME
|
|
Learn what is unique about a first-in-kind bispecific antibody that simultaneously binds and neutralizes VEGF-A and angiopoietin-2.
|
|
Continue
|
|
|
|
When vitrectomy offers viable therapeutic option for DME
|
|
In an era when pharmacologic therapy has become the mainstay for diabetic macular edema, pars plana vitrectomy may be a reasonable alternative in appropriate patients.
|
|
Learn more
|
